Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s current pause of U.S. cases, according to a poll by BTIG.
Doctors expect Boston Scientific to lead PFA race, survey finds Read More »
La realización de tests neuropsicológicos con realidad virtual no es ni una mera posibilidad teórica ni tampoco algo experimental, al haber actualmente empresas especializadas que brindan esta herramienta para evaluar. Así, los profesionales ya pu …
Los nuevos test neuropsicológicos con realidad virtual Read More »
The new estimate nearly doubles the company’s previous report of 100 million affected individuals, already the largest healthcare data breach ever reported to federal regulators.
UnitedHealth hikes number of Change cyberattack breach victims to 190 million Read More »
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives Read More »
Following disappointing clinical trial results for AK006, Allakos will cut its workforce down to under 20 employees as it explores strategic alternatives.
Allakos Will Axe 75% of Workforce, Drop Hives Candidate Read More »
After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed greater improvements after 96 weeks of treatment in an advanced disease population.
Akero Rebounds as Benefit Deepens in Key Mid-Stage MASH Trial Read More »
La tecnología 5G ya es una realidad en el mundo actual y las economías globales ya están experimentando los diferentes beneficios que ofrece, como velocidades de internet más rápidas, menor latencia y conexiones más confiables que las generacion …
The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for patients with Alzheimer’s, could help with Leqembi’s thus far disappointing uptake and sales.
Biogen, Eisai Win Nod for Monthly Leqembi Maintenance Amid Stagnant Sales Read More »
Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were takin Wegovy alone.
Veru’s Drug Spares Lean Mass in Overweight, Obese Adults on Wegovy Read More »
Unos investigadores han hecho un importante avance en el estudio del sarcoma de Ewing, el segundo tumor óseo más frecuente entre niños y adolescentes. Esta nueva investigación ha sido realizada por un equipo que incluye, entre otros, a la Dra. Mariona Chicó …
Paso adelante en la comprensión del sarcoma de Ewing Read More »
